Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01215344 · FLOW

Participant flow

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade · Source last updated 2018-05-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    VELCADE, Lenalidomide, Dexamethasone VELCADE: 1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle Lenalidomide: 25 mg by mouth on days 1-4 of each cycle Dexamethasone: 20 mg the day before and the day after receiving VELCADE DVT prophylaxis: At least one asprin 81 mg per day. Other option per physician's choice Bisphosphonates: Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.
    id
    FG000
    title
    VRD (VELCADE, Lenalidomide, Dexamethasone)
  2. description
    VELCADE, liposomal doxorubicin, dexamethasone VELCADE: 1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle DVT prophylaxis: At least one asprin 81 mg per day. Other option per physician's choice Liposomal doxorubicin: 30 mg/m2 on day 4 of each cycle Dexamethasone: 40 mg by mouth on days 1-4, 8-11, and 15-18 of cycle 1 and days 1-4 on cycle 2-4
    id
    FG001
    title
    VDD (VELCADE, Liposomal Doxorubicin, Dexamethasone)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        33
      2. group Id
        FG001
        num Subjects
        3
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        23
      2. group Id
        FG001
        num Subjects
        3
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        10
      2. group Id
        FG001
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Participants participated in this trial at Vanderbilt-Ingram Cancer Center in Nashville, TN and the Boston Baskin Cancer Group in Memphis, TN. A total of 52 people consented to take part in this study and 15 were ineligible. One participant had disease progression before beginning treatment and wasn't assigned to a treatment arm.
Complete source fields
groups
  1. description
    VELCADE, Lenalidomide, Dexamethasone VELCADE: 1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle Lenalidomide: 25 mg by mouth on days 1-4 of each cycle Dexamethasone: 20 mg the day before and the day after receiving VELCADE DVT prophylaxis: At least one asprin 81 mg per day. Other option per physician's choice Bisphosphonates: Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.
    id
    FG000
    title
    VRD (VELCADE, Lenalidomide, Dexamethasone)
  2. description
    VELCADE, liposomal doxorubicin, dexamethasone VELCADE: 1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle DVT prophylaxis: At least one asprin 81 mg per day. Other option per physician's choice Liposomal doxorubicin: 30 mg/m2 on day 4 of each cycle Dexamethasone: 40 mg by mouth on days 1-4, 8-11, and 15-18 of cycle 1 and days 1-4 on cycle 2-4
    id
    FG001
    title
    VDD (VELCADE, Liposomal Doxorubicin, Dexamethasone)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        33
      2. group Id
        FG001
        num Subjects
        3
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        23
      2. group Id
        FG001
        num Subjects
        3
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        10
      2. group Id
        FG001
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Participants participated in this trial at Vanderbilt-Ingram Cancer Center in Nashville, TN and the Boston Baskin Cancer Group in Memphis, TN. A total of 52 people consented to take part in this study and 15 were ineligible. One participant had disease progression before beginning treatment and wasn't assigned to a treatment arm.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice